Companies › Editas Medicine
1 active drug program in 2 registered trials: 2 Phase 1; Hematology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EDIT-301 (renizgamglogene autogedtemcel, reni-cel) ex vivo base editing of hematopoietic stem cells targeting BCL11A to increase fetal hemogl | BCL11A | Phase 1 | Sickle Cell Disease; Transfusion Dependent Beta Thalassemia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04853576 | EDIT-301 (renizgamglogene autogedtemcel, reni-cel) | Phase 1 | Sickle Cell Disease | Hematology | Aug 2025 |
| NCT05444894 | EDIT-301 (renizgamglogene autogedtemcel, reni-cel) | Phase 1 | Transfusion Dependent Beta Thalassemia | Hematology | Sep 2025 |
Cash and short-term investments of $190m on 2026-09-30; operating cash outflow about $99m a year; runway about 23 months at that burn, to Aug 2028
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.